Trastuzumab: Clinical Trials

992 trials of Trastuzumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

489 completed, 115 recruiting, 115 terminated, 114 unknown. 607 Phase 2, 213 Phase 1, 198 Phase 3, 21 Not applicable, 16 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2607Completed 270, Terminated 82, Unknown 78, Recruiting 74, Active not recruiting 52, Not yet recruiting 30, Withdrawn 20, Suspended 1
Phase 1213Completed 117, Terminated 35, Active not recruiting 18, Recruiting 18, Unknown 13, Withdrawn 8, Not yet recruiting 2, Suspended 2
Phase 3198Completed 101, Recruiting 32, Active not recruiting 23, Unknown 17, Terminated 16, Not yet recruiting 6, Withdrawn 3
Not applicable21Completed 9, Unknown 5, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 416Completed 5, Recruiting 5, Active not recruiting 2, Terminated 2, Not yet recruiting 1, Unknown 1
Early Phase 16Completed 2, Withdrawn 2, Terminated 1, Unknown 1

Follow Trastuzumab: new trials by email Literature Review of Trastuzumab trials Research Report on Trastuzumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Phase 3RecruitingSWOG Cancer Research Network5622027-03-092026-10-13
Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer
Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer
Phase 2Not yet recruitingPolly A. Niravath, MD302026-12-312026-08-19
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Phase 2Not yet recruitingNovartis Pharmaceuticals512026-12-152026-09-18
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis)
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1282026-12-012026-11-16
HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer
HLX22, Trastuzumab, XELOX Chemotherapy - HER2-Positive, Limited Metastatic
Phase 2Not yet recruitingShanghai Zhongshan Hospital302026-12-012026-11-17
Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors
FMC-242, Trastuzumab (or biosimilar), Fulvestrant (or generic) - Locally Advanced Solid Tumor
Phase 1 / Phase 2Not yet recruitingFrontier Medicines Corporation2822026-12-012026-11-18
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer
Phase 3RecruitingDaiichi Sankyo2002026-11-042026-11-17
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
Chimeric receptor T-cells + Trastuzumab, Fludarabine and Cyclophosphosphamide - HER2+ Advanced Breast Cancer, Other Solid Tumors
Phase 1 / Phase 2Not yet recruitingNational University Hospital, Singapore362026-11-012025-09-23
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients
HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer
Phase 2Not yet recruitingShanghai Henlius Biotech902026-10-312026-09-17
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
trastuzumab, bevacizumab - Ovarian Cancer
Phase 3RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.4202026-10-202026-11-04
A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy
Trastuzumab + Durvalumab + FLOT - Gastric Cancer
Phase 2RecruitingSamsung Medical Center202026-10-062026-11-02
HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy
- Oral paclitaxel solution: 200 mg/m² orally twice daily on Day 1 and Day 8 of each cycle, subcutaneous pertuzumab and trastuzumab fixed-dose combination for a total of 6 cycles - HER 2 Positive Advanced Breast Cancer
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University652026-10-012026-09-30
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC)
Phase 2Not yet recruitingFudan University3582026-10-012026-10-02
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2402026-10-012026-07-21
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer
Phase 2Not yet recruitingFujian Cancer Hospital502026-09-302026-08-14
Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer
Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital312026-09-012026-10-19
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer
Phase 2Not yet recruitingShengjing Hospital332026-09-012026-08-31
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
cDC1 Vaccine, Trastuzumab, Nivolumab - Breast Cancer, Leptomeningeal Disease
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute302026-08-012026-07-10
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer
Phase 1 / Phase 2RecruitingLiu Shu302026-07-292026-08-04
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab. - Advanced HER2-positive Breast Cancer
Phase 2RecruitingFudan University1402026-07-282026-11-02

Showing 20 of 992. Sign in to see all of them.

Conditions studied

Breast Neoplasms (645)  ·  Stomach Neoplasms (81)  ·  Neoplasm Metastasis (59)  ·  Neoplasms (40)  ·  Breast Neoplasms, Male (30)  ·  Colorectal Neoplasms (29)  ·  Brain Neoplasms (26)  ·  Carcinoma, Non-Small-Cell Lung (22)  ·  Esophageal Neoplasms (20)  ·  Inflammatory Breast Neoplasms (20)  ·  Pancreatic Neoplasms (13)  ·  Triple Negative Breast Neoplasms (13)  ·  Endometrial Neoplasms (11)  ·  Lung Neoplasms (11)  ·  Ovarian Neoplasms (11)

Sponsors

Hoffmann-La Roche (89)  ·  National Cancer Institute (NCI) (44)  ·  Fudan University (24)  ·  Novartis Pharmaceuticals (24)  ·  Memorial Sloan Kettering Cancer Center (19)  ·  Dana-Farber Cancer Institute (18)  ·  Genentech, Inc. (14)  ·  M.D. Anderson Cancer Center (11)  ·  SCRI Development Innovations, LLC (10)  ·  City of Hope Medical Center (9)  ·  NSABP Foundation Inc (9)  ·  Pfizer (9)  ·  H. Lee Moffitt Cancer Center and Research Institute (8)  ·  Jonsson Comprehensive Cancer Center (8)  ·  Sanofi (8)

Countries

United States (448)  ·  China (209)  ·  Spain (140)  ·  France (135)  ·  Italy (128)  ·  Germany (116)  ·  United Kingdom (96)  ·  South Korea (93)  ·  Belgium (91)  ·  Canada (82)  ·  Brazil (63)  ·  Poland (61)  ·  Australia (59)  ·  Russia (55)  ·  Taiwan (52)

Top investigators

Norman Wolmark, MD (9)  ·  Nancy Lin, MD (8)  ·  Denise A. Yardley, MD (4)  ·  Mothaffar Rimawi, MD (4)  ·  Yelena Janjigian, MD (4)  ·  Adrienne Waks, MD (3)  ·  Andrea De Matteis, M.D. (3)

Results publications

PMID 26101239, PMID 20728210, PMID 28057664, PMID 39024777, PMID 39613746, PMID 10561296, PMID 15139054, PMID 16236737, PMID 16236738, PMID 17208639, PMID 21730275, PMID 22149875, PMID 22153890, PMID 22508812, PMID 23764181, PMID 24077916, PMID 2470152, PMID 25332249, PMID 26342236, PMID 26857702, PMID 27179402, PMID 29530935, PMID 29804905, PMID 30808774, PMID 31622131, PMID 33357420, PMID 33369581, PMID 34037241, PMID 34252375, PMID 35181666, PMID 35610260, PMID 35623069, PMID 37597578, PMID 38979716, PMID 39191270, PMID 39368039, PMID 40341124, PMID 10080589, PMID 10628376, PMID 10766175, PMID 11230490, PMID 11248153, PMID 11352950, PMID 11396203, PMID 11454999, PMID 11745247, PMID 12048273, PMID 12138395, PMID 12907602, PMID 12954578

NIH funding

2023 (14), 2009 (12), 2008 (11), 2014 (9), 2017 (8), U10CA180868 (8), 2018 (7), U10CA031946 (6), 2015 (5), P30CA033572 (5), P30CA015083 (4), P30CA016672 (4), U10CA012027 (4), U10CA021115 (4), 2005 (3)